Content uploaded by Ethan Basch
Author content
All content in this area was uploaded by Ethan Basch on Jun 20, 2014
Content may be subject to copyright.
MONOGRAPH
FROM NATURAL STANDARD
Catherine Ulbricht, PharmD, Column Editor
Lavender (Lavandula angustifolia Miller)
Ethan Basch, MD
Ivo Foppa, MD, PhD
Richard Liebowitz, MD
Jamie Nelson, PharmD
Michael Smith, MRPharmS, ND
David Sollars, MAc, HMC
Catherine Ulbricht, PharmD
Ethan Basch is affiliated with the Natural Standard Research Collaboration. Ivo
Foppa is affiliated with Harvard University. Richard Liebowitz is affiliated with Duke
University. Jamie Nelson is affiliated with the University of Rhode Island. Michael
Smith is affiliated with the Canadian College of Naturopathic Medicine. David Sollars
is affiliated with the New England School of Acupuncture. Catherine Ulbricht is affili
-
ated with Massachusetts General Hospital. All are members of Natural Standard Re
-
search Collaboration (www.naturalstandard.com).
The information in this monograph is intended for informational purposes only, and
is meant to help users better understand health concerns. Information is based on re
-
view of scientific research data, historical practice patterns, and clinical experience.
This information should not be interpreted as specific medical advice. Users should
consult with a qualified healthcare provider for specific questions regarding therapies,
diagnosis and/or health conditions, prior to making therapeutic decisions.
Copyright 2003 Natural Standard Inc. Reprinted with permission.
Journal of Herbal Pharmacotherapy, Vol. 4(2) 2004
http://www.haworthpress.com/web/JHP
Digital Object Identifier: 10.1300/J157v04n02_07 63
ABSTRACT. An evidence-based systematic review including scien
-
tific evidence, expert opinion, folkloric precedent, history, pharmacol
-
ogy, kinetics/dynamics, interactions, adverse effects, toxicology, and
dosing.
[Article copies available for a fee from The Haworth Document Deliv
-
ery Service: 1-800-HAWORTH. E-mail address: <docdelivery@haworthpress.
com> Website: <http://www.HaworthPress.com>]
KEYWORDS. Lavender, Lavendula angustifolia Miller, limonene, perillyl
alcohol, POH
SYNONYMS/COMMON NAMES/RELATED SUBSTANCES
Common lavender, English lavender, garden lavender, Lavandula
burnamii, Lavandula dentate, Lavandula dhofarensis, Lavandula latifolia,
Lavandula officinalis L., Lavandula stoechas, limonene, perillyl alcohol,
pink lavender, POH, true lavender, white lavender.
CLINICAL BOTTOM LINE/EFFECTIVENESS
Brief Background
Lavender is native to the Mediterranean, the Arabian Peninsula, Rus-
sia, and Africa. It has been used cosmetically and medicinally through-
out history. In modern times, lavender is cultivated around the world
and the fragrant oils of its flowers are used in aromatherapy, baked
goods, candles, cosmetics, detergents, jellies, massage oils, perfumes,
powders, shampoo, soaps, and tea. English lavender (L. angustifolia)is
the most common species of lavender used, although other species are in
use, including Lavandula burnamii, L. dentate, L. dhofarensis, L. latifolia,
and L. stoechas.
64 JOURNAL OF HERBAL PHARMACOTHERAPY
Many people find lavender aromatherapy to be relaxing, and it has
been reported to have anxiolytic effects in several small, methodologi
-
cally flawed trials. Overall, the weight of the evidence suggests a small
positive effect, although additional data from well-designed studies are
required before the evidence can be considered strong.
Lavender aromatherapy is also used as a hypnotic, although there is
insufficient evidence in support of this use.
Small phase I human trials of the lavender constituent perillyl alcohol
(POH) for cancer have suggested safety and tolerability (up to 1200 mg/
m
2
four times/day), although efficacy has not been demonstrated.
Scientific Evidence for Common/Studied Uses
Historical or Theoretical Uses that Lack Sufficient Evidence
Acne, alopecia, analgesia, angioprotectant, anticolic, anticonvulsant,
antidepressant, antiflatulant, antifungal, anti-inflammatory,
1
antimicro-
bial,
2
antioxidant,
3
antipyretic, antiseptic, anxiety, appetite stimulant,
asthma, balenotherapy (functional circulatory disorders), cholagogue,
choleretic, chronic bronchitis, ciatrizant, cordial, diabetes,
4
diuretic,
douche, emmenagogue, exercise recovery, gas, hangovers, hyptension,
infertility, insect repellent, insomnia,
5
lice, migraine, non-tubercular
mycobacteria (NTM),
6
parasitic infection, psychosis, rheumatism,
Roehmheld’s syndrome, rubefacient, toothache, varicose veins, vomit
-
ing.
Expert Opinion and Historic Precedent
Lavender is rich in volatile oils and has been used for centuries both
as a fragrance and medicinal herb. Linen bags containing lavender
flowers were commonly placed under pillows for their alleged soporific
properties.
Lavender is thought by some experts to possess antibacterial proper
-
ties. Currently, lavender oil is often used as an aromatherapeutic anxio
-
Monograph from Natural Standard 65
Indication
Evidence Grade
Anxiety (aromatherapy)
B
Hypnotic/Sleep (aromatherapy)
C
Perineal discomfort following childbirth (bathing)
C
Spasmolytic (oral)
C
Antibiotic (topical)
C
Cancer (oral perillyl alcohol [POH])
C
A
B
C
D
E
GRADING
SYSTEM
LINK
lytic and hypnotic, including in the hospital setting.
7
Infusions of
lavender flowers have been used for similar indications.
Brief Safety Summary
Likely Safe: When consumed in amounts commonly found in foods and
beverages (received Generally Recognized as Safe [GRAS] status for food
use in the United States), or when used in recommended oral/topical doses.
Possibly Unsafe: When used concomitantly with central nervous system
depressants, due to potential additive effects.
8,9,10
DOSING TOXICOLOGY
General
Recommended doses are based on those most commonly used in
available trials, or on historical practice. These doses have not necessarily
been shown effective. Anecdotal dosing regimens are based on traditional
health practice patterns and/or expert opinion. With natural products it is
often not clear what the optimal doses are to balance efficacy and safety.
Preparation of products may vary from manufacturer to manufacturer,
and from batch to batch within one manufacturer. Because it is often not
clear what are the active components of a product, standardization may
not be possible, and the clinical effects of different brands may not be
comparable.
Standardization
•
Lavender products are not standardized in the United States.
•
Each species of lavender has unique chemical constituents and ac
-
tivity.
•
The flowers are the part of lavender most often used medicinally.
Adult Dosing (18 Years and Older)
Oral
Tea: One to two teaspoons of the herb taken as a tea (based on anecdote
and expert opinion). The tea can be made by steeping 2 U.S. teaspoons (10
grams) of leaves in 250 mL (1 cup) boiling water for 15 minutes.
66 JOURNAL OF HERBAL PHARMACOTHERAPY
Oral Perillyl Alcohol (POH): In preliminary (phase I) cancer trials,
doses between 800-1200 mg/m
2
four times/day in a 50:50 POH:soybean
oil preparation were tolerated with minimal adverse effects (efficacy has
not been demonstrated).
11,12
Inhalation (Aromatherapy)
Aromatherapy: Two to four drops in 2-3 cups boiling water; inhale va
-
pors. Aromatherapy can be administered intermittently or daily as needed
(based on anecdote and expert opinion).
Topical/Infusion
Bath Additive: For perianal discomfort after childbirth, 6 drops of laven
-
der oil has been studied as a bath additive (no specific brand).
13
Those
wishing to use the whole flower may add 1/4 to 1/2 cup of dried laven-
der flowers to hot bath water (based on anecdote and expert opinion).
Massage Therapy: One to four drops per tablespoon of base oil (based
on anecdote and expert opinion).
Pediatric Dosing (Younger Than 18 Years)
Insufficient data available.
Toxicology
There have been rare reports of sensitization after topical use of lav-
ender.
14,15
Lavender has been reported to exert ‘narcotic-like’ effects in both an
-
imals
8,9
and humans.
5
PRECAUTIONS/CONTRAINDICATIONS
Allergy
Caution should be exercised in patients with known allergy/hyper
-
sensitivity to lavender. Persons with allergy to lavender may experience
mild local skin reactions after topical use of lavender oil.
14,16
Adverse Effects
General: In recommended doses, lavender is generally considered to be
well-tolerated, with minimal adverse effects.
7,13,17
Monograph from Natural Standard 67
Dermatologic: There have been case reports of mild dermatitis follow
-
ing the use of topical lavender oil.
18
One individual developed an itchy
dermatitis on his face after using lavender oil on his pillow.
16
Patch test
-
ing subsequently confirmed a positive allergy to lavender. There have been
reports of photosensitization and changes in skin pigmentation after the use
of topical products containing lavender oil.
19,14
Neurologic/CNS: Central nervous system depression has rarely been re
-
ported with aromatherapy,
5,11
and additive narcotic effects have been noted
in rats when taken orally concomitantly with barbiturates or chloral hy
-
drate.
9,20
Hematologic: Reversible neutropenia has been noted after high oral
doses of perillyl alcohol (POH), a monoterpene constituent of lavender, in
patients with untreatable malignancies (on multiple chemotherapy regi
-
mens).
11
Gastrointestinal: Nausea, vomiting and anorexia have been reported af-
ter large oral doses of lavender (>5.0 g/day),
21,22
and after large doses of the
lavender constituent perillyl alcohol (POH).
12
Precautions/Warnings/Contraindications
Avoid in patients with a known allergy/hypersensitivity to lavender,
based on several case reports of dermatitis in patients with lavender al-
lergy.
16,19
Use cautiously in patients who are currently taking drugs that depress
the central nervous system, because concomitant use of lavender may
exacerbate sedation.
5,9,10
Pregnancy and Lactation
Not recommended due to lack of sufficient data.
Due to its purported properties as an emmenagogue, excessive inter
-
nal use should be avoided during pregnancy. However, there is no de
-
finitive evidence in this area.
INTERACTIONS
Lavender/Drug Interactions
Sedating Drugs: In rats, concomitant use of lavender and pentobarbital
or chloral hydrate has significantly increased sleeping time and narcotic ef
-
68 JOURNAL OF HERBAL PHARMACOTHERAPY
fects.
9,20
Concurrent use with other sedative or hypnotic agents theoreti
-
cally may act in an additive or synergistic fashion.
Anticoagulants, NSAIDs, Anti-Platelet Agents: Lavender contains vary
-
ing amounts of coumarins and may therefore theoretically increase the ef
-
fect of anticoagulant medications.
Anti-Seizure Medications: Lavender enhances GABA effects and may
therefore intensify the sedative effects of GABA-dependent antiepileptics.
HMG-CoA Reductase Inhibitors, Niacin, Cholesterol Lowering Agents;
Theoretical Positive Interaction: Lavender may act in an additive fashion
with cholesterol-lowering agents: Cineole, a cyclic monoterpene found in
lavender, lowers cholesterol in rats via inhibition of the HMG-CoA en
-
zyme; the lavender constituent perillyl alcohol (POH) has been shown to
inhibit the conversion of lathesterol to cholesterol.
23,24
Lavender/Herb/Supplement Interactions
Sedating Agents: Lavender has been found to have sedative effects in
animal models, and acts additively with sedatives including pentobarbital
and chloral hydrate.
9,20
In theory, it may intensify the effects of other seda-
tive agents such as kava or valerian root.
Anticoagulant Herbs/Supplements: Lavender contains varying amounts
of coumarins and may therefore theoretically increase the effect of antico-
agulant medications.
Lavender/Food Interactions
Insufficient available evidence.
Lavender/Lab Interactions
Low Density Lipoprotein (LDL), Total Cholesterol, High Density Lipo-
protein (HDL): Based on animal studies, oral lavender may act similarly to
HMG-CoA reductase inhibitors and lower total cholesterol/LDL while
raising HDL.
23,24
MECHANISM OF ACTION
Pharmacology
Lavender is comprised of over 100 constituents, including linalool,
perillyl alcohol, linalyl acetate, camphor, limonene, tannins, triterpenes,
coumarins, cineole, and flavonoids.
Linalool has been shown to reduce motor activity in mice due to a
Monograph from Natural Standard 69
dose-related binding to glutamate, a primary excitatory neurotransmitter
of the central nervous system, and it has been suggested that hypnotic
and anticonvulsant effects of lavender may be due to the potentiation of
the neurotransmitter GABA.
25
The mechanism of lavender’s spasmolytic activity has not been fully
elucidated. Gamez et al. studied the antispasmodic effect of L. dentate (a
lavender species) in vitro.
26
An observed antagonism of acetylcholine-in
-
duced muscle contractions was attributed largely to cineole. Lis-Balchin et
al. observed that the linalool and linalyl acetate in L. angustifolia oil can in
-
duce cAMP-mediated relaxation of guinea pig ileum smooth muscle.
27
The
authors postulated a cAMP-based mechanism for lavender’s purported
physiological effects on sympathetic nervous system activity.
Components of lavender appear to have cytotoxic properties. Fulton
et al. demonstrated cell proliferating effects of perillyl alcohol (POH)
on smooth muscle cell cultures.
28
Both limonene and POH have been
shown to inhibit tumor growth in rats by blocking initiation and by pro-
moting apoptosis.
29,30,31
One in vitro study evaluated the effects of POH in
lung carcinogenesis, and described an inhibitory effect on farnesylation, a
step towards activation of the oncogene K-ras.
32
The lipid-lowering effect of lavender has been attributed to the con-
stituent cineole, a cyclic monoterpene which lowers cholesterol in rats
via inhibition of the HMG-CoA enzyme.
23
The lavender constituent
perillyl alcohol (POH) has been shown to inhibit the conversion of lathesterol
to cholesterol.
24
Caffeic acid, a constituent of lavender, has been demonstrated to pos-
sess antioxidant effects in vitro.
33
Pharmacodynamics/Kinetics
Topical: Lavender oil is quickly absorbed by the skin. The constituents
linalool and linalyl acetate are detectable in the blood five minutes after
topical application, peak at 19 minutes, and largely disappear from the
blood within 90 minutes.
34
Oral: The constituents limonene and perillyl alcohol (POH) are metabo
-
lized into perillic acid (PA) and dihydroperillic acid (DHPA). In rats fed a
diet containing POH or limonene, peak levels of PA can be seen at 1-2.5
hours, peak levels of DHPA are noted at 2-3.5 hours, and half-lives for
each metabolite are 1-2 hours.
30
POH, PA, and DHPA are detectable in
subjects’ urine following high doses of POH ingestion. Approximately
9% of the total dose can be recovered in the first 24 hours. PA is the ma
-
jor metabolite found, with <1% of recovered POH.
70 JOURNAL OF HERBAL PHARMACOTHERAPY
The absorption of POH does not appear to be affected by concomi
-
tant ingestion of foods.
11,12
HISTORY
The name lavender is derived from the Latin lavare, meaning to wash.
In ancient Greece, Persia and Rome, it was used as a perfume in baths and
laundry, and as an antiseptic. Ancient Egyptians created mummification
casts by soaking linen in oil of lavender containing asphalt, then wrapping
the bodies with these and drying them in the sun until the casts were hard.
Lavender has been renowned as a ‘healing agent’ in India and Tibet. In Ti
-
betan Buddhist medicine, lavender is still used to treat insanity and psycho-
ses. Today, in Europe and the Americas, lavender is often used as an
anxiolytic and sleep aid.
EVIDENCE TABLE
Monograph from Natural Standard 71
Condition Study Design Author,
Year
N Statistically
Significant?
Quality of
Study
0-2=poor
3-4=good
5=excellent
Magnitude
of Benefit
ARR NNT Comments
Anxiety Not randomized,
controlled
Saeki,
2000
10 Yes 1 Small NA NA Poor
description of
methodology;
unclear
blinding or
randomization.
Anxiety Randomized,
controlled
Dunn,
1995
12
2
Yes 1 Small NA NA Initial benefit
dissipated
after first
session.
Anxiety Not randomized,
controlled
Motomura,
1998
42 Yes 0 Large NA NA Small study,
results unclear
due to lack of
randomization.
Anxiety Case series Itai, 2000 14 Yes NA Large NA NA No significant
difference
compared to
odorless smell.
Hypnotic Case series Hardy,
1995
4 NA NA None NA NA Small series
using
aromatherapy.
Perineal
relief
following
childbirth
Double-blind,
randomized,
controlled
Dale,
1994
63
5
No 3 None NA NA Subjective
outcome
measure,
incomplete
data, no
difference
found.
Tumor
regression
Case series
(phase I clinical
trial)
Ripple,
1998
18 NA 1 NA NA NA Uncontrolled
trial using
perillyl alcohol
(POH).
EVIDENCE DISCUSSION
Anxiety (Aromatherapy)
Summary: In general, the evidence supporting lavender aromatherapy as
an anxiolytic is weak. There are conflicting results from methodologically
flawed studies, with some showing lack of effect. However, overall, the
weight of the evidence suggests a small positive effect in relieving anxiety.
Further study through well-designed randomized trials would strengthen this
case. However, there are inherent difficulties involved with designing blind
-
ing or placebo control for study of an olfactory therapy. These difficulties
must be overcome before compelling results can be generated.
Evidence: Saeki et al. attempted to demonstrate that lavender aromatherapy
via footbath produced anxiolytic effects compared to placebo.
17
This “be-
fore and after” study, which consisted of 10 subjects, concluded that a hot
footbath with lavender oil is associated with small but significant changes
in autonomic activity. However, the incomplete description of methodol-
ogy and analysis make results difficult to interpret.
Dunn et al. conducted a randomized, single-blind study in 122 inten-
sive care unit patients, allocated to one of three groups: body massage
with grapeseed oil, body massage with lavender oil, or undisturbed
rest.
7
Psychological endpoints were assessed using an arbitrary 4-point
scale, and physiological endpoints included blood pressure, heart rate,
and breaths-per-minute. Treatment ranged from one to three 30-minute
sessions, 24 hours apart. All patients received at least one session; 66
patients completed three sessions. After the first session, patients who
had received a massage with lavender oil had significantly less anxiety
than the group who rested. This difference was not maintained in the
following sessions. It is not clear to what extent the lack of dou-
ble-blinding, or the high dropout rate, affected results.
Motomura et al. conducted an experiment in which 42 students were di
-
vided into three groups: Group 1 experienced a “stressful condition;” group
2 experienced a “stressful condition” with the addition of lavender odor;
group 3 experienced a “non-stressful condition.” Stress was evaluated
based on a Japanese version of Cox and Mackay’s stress/arousal adjective
checklist. The experiment found that scores in the lavender group were sig
-
nificantly lower than the group who was stressed and did not receive laven
-
der therapy.
35
However, blinding and randomization were not clearly
described.
In a case series consisting of 14 female, chronic renal failure patients
on hemodialysis, Itai et al. evaluated the effect of lavender oil on mood
72 JOURNAL OF HERBAL PHARMACOTHERAPY
using the Hamilton rating scale for depression (HAMD) and the Hamil
-
ton rating scale for Anxiety (HAMA).
36
Compared to natural smell (base
-
line), lavender was observed to decrease anxiety as evidenced by the
HAMA scale (P = 0.05). Lavender did not significantly alter patients’
HAMD scores from baseline. When lavender was compared to odorless
conditions, the difference in HAMA and HAMD scores was minimal.
Buckle compared therapeutic benefits of oils from two different spe
-
cies of lavender (L. angustifolia and L. burnatti) applied by massage to 28
hospitalized patients.
37
A semi-structured interview to collect qualitative,
subjective data was used several days after treatment. The study reported
that L. burnatti had significantly more relaxing effects than its counterpart.
However, further details of statistical analysis or methodology were in-
complete, thus raising question about the results.
Hypnotic/Sleep (Aromatherapy)
Summary: Many experts and patients believe that lavender aromatherapy
is an effective hypnotic. Although preliminary evidence suggests some
hypnotic effects of lavender, there are no randomized trials in the available
literature. Without further study, the current evidence can only be consid-
ered equivocal. However, there are inherent difficulties involved with de-
signing blinding or placebo control for study of an olfactory therapy. These
difficulties must be overcome before compelling results can be generated.
Evidence: Hardy et al. evaluated aromatherapeutic lavender as an alter-
native to conventional hypnotics in four geriatric patients.
5
Sleep hours
were monitored during three two-week phases. During phase I, subjects
continued their current hypnotic (temazepam, promazine, chlormethiazole).
Phase II involved a withdrawal and washout period. During phase III, lav
-
ender oil was introduced into the patients’ sleeping quarters via an odor dif
-
fuser. The results demonstrated that hours asleep were comparable to the
number of hours asleep during phase I of the trial for all four participants.
However, without controls or blinding, results can only be considered pre
-
liminary.
Diego et al. demonstrated the effects of three-minute aromatherapy
sessions using a 10% lavender oil concentration on participants’ brain
waves via electroencephalogram (EEG).
38
The EEG reading was re
-
corded prior, during, and after sessions. Alpha and beta activity were found
to increase after the inhalation of lavender. Notably, increased frontal alpha
and beta activity have been associated with increased drowsiness, which
provides mechanistic supportive evidence for this purported indication.
Monograph from Natural Standard 73
Perineal Discomfort Following Childbirth (Baths)
Summary: There is insufficient scientific evidence regarding the use of
lavender oil baths for the relief of postpartum perineal discomfort.
Evidence: Dale and Cornwell examined the effect of lavender oils baths
on perineal discomfort in 635 postpartum women in a randomized trial.
13
Subjects were divided into three groups: Group 1 added a natural lavender
oil extract to baths, group 2 added a synthetic lavender oil to baths, and the
third group used an unspecified control substance that had U.S. “Generally
Recognized As Safe” status. The control was reported to be distinguishable
from the other two oils by smell, and in efforts to compensate for this, pa
-
tients were informed that the trial was testing “different bath additives.” To
evaluate discomfort, women were asked to complete visual analogue
scales (VAS), a subjective questionnaire used to evaluate the degree of dis-
comfort over the 10 days of the experiment. Data were obtained from
~60% (n = 386) of participants. Although this trial found no significant dif-
ferences in perineal relief between the groups, the large dropout rate and
lack of information about the control substance (which could have been ac-
tive) raise doubts about the validity of results.
Spasmolytic (Oral)
Summary: Preliminary data from animal and in vitro studies indicate a
potential spasmolytic effect of lavender oil inhalation. However, human
evidence is lacking.
Animal Data: A variety of lavender species have demonstrated an abil-
ity to inhibit stimulated muscle contractions in the ileum and conjunctiva of
animal models.
26,39,40,27,41
Antibiotic (Topical)
Summary: Preliminary data from in vitro studies suggest that lavender
oils possess antibiotic activity. However, this has not been tested in animal
or human studies, and results cannot be considered clinically relevant.
In Vitro Data: Gabbrielli et al. demonstrated in vitro activity of lavender
oil (L. angustifolia and L. latifolia) against various strains of non-tubercular
Mycobacterium.
6
Nelson et al. found documented activity of 2% to
0.12% (v/v) lavender oils against both methicillin-resistant Staphylo
-
coccus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
2
74 JOURNAL OF HERBAL PHARMACOTHERAPY
Cancer (Oral)
Summary: Preliminary data from animal studies suggest an antineoplastic
effect of oral perillyl alcohol (POH) and other monoterpenes found in lav
-
ender. Studies have focused on cancers of the pancreas, breast, and intes
-
tine. Small phase I studies have been conducted in humans, suggesting
safety and tolerability of POH (up to 1200 mg/m
2
four times/day), but effi
-
cacy has not been established.
Animal Data: Elegbede et al. and Haag et al. demonstrated regression of
primary mammary tumors in rats after supplementing diets with limonene
and POH (lavender constituents).
29,30
Burke et al. documented inhibition of
pancreatic adenocarcinoma growth in hamsters using a similar diet.
42
Reddy et al. found a significant chemoprotective effect of oral POH on
carcinogenesis of the large and small intestines in rats.
43
Human Evidence: In a phase I clinical trial, Ripple et al. examined
the potential of POH to suppress tumor growth in humans.
11
This study
consisted of 18 patients with advanced malignancies of various origins,
refractory to standard therapies. POH was formulated in gelatin cap-
sules containing 250 mg of POH and 250 mg of soybean oil. Prior to re-
ceiving POH, as a washout, patients did not receive hormonal or
immunological therapy for two weeks, or chemotherapy/radiation for
four weeks. Patients were divided into three groups: 800 mg/m
2
/dose;
1600 mg/m
2
/dose; or 2400 mg/m
2
/dose, three times/day. Although no
objective tumor responses were noted, disease stabilization was noted
in several patients for up to six months. POH was generally well toler-
ated, although dose-dependent gastrointestinal side effects (nausea,
early satiety) and fatigue led to withdrawal of one patient from the
study.
In a second case series, the same authors examined the effects of
more frequent administration at slightly lower doses.
12
Nineteen patients
with various malignancies, refractory to standard treatment, were treated
at the following doses: 800 mg/m
2
/dose; 1200 mg/m
2
/dose; or 1600 mg/
m
2
/dose, four times/day. The maximum tolerated dose of POH given
continuously four times/day was 1200 mg/m
2
/dose. Patterns of disease
progression similar to the initial trial were observed at all doses. Al
-
though promising, these results must be further evaluated through con
-
trolled studies before a recommendation can be made. Nonetheless,
these small studies suggest safety and tolerability of POH at doses up to
1200 mg/m
2
four times/day.
Monograph from Natural Standard 75
REFERENCES
1. Kim HM, Cho SH. Lavender oil inhibits immediate-type allergic reaction in
mice and rats. J Pharm Pharmacol 1999;51(2):221-226.
2. Nelson RR. In-vitro activities of five plant essential oils against methicillin-re
-
sistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.J
Antimicrob Chemother 1997;40(2):305-307.
3. Siurin SA. [Effects of essential oil on lipid peroxidation and lipid metabolism in
patients with chronic bronchitis]. Klin Med (Mosk) 1997;75(10):43-45.
4. Gamez MJ, Zarzuelo A, Risco S, et al. Hypoglycemic activity in various species
of the genus Lavandula. Part 2: Lavandula dentata and Lavandula latifolia. Pharmazie
1988;43(6):441-442.
5. Hardy M, Kirk-Smith MD, Stretch DD. Replacement of drug treatment for in
-
somnia by ambient odour. Lancet 1995;346(8976):701.
6. Gabbrielli G, Loggini F, Cioni PL, et al. Activity of lavandino essential oil
against non-tubercular opportunistic rapid grown mycobacteria. Pharmacol Res Commun
1988; 20 Suppl 5:37-40.
7. Dunn C, Sleep J, Collett D. Sensing an improvement: An experimental study to
evaluate the use of aromatherapy, massage and periods of rest in an intensive care unit.
J Adv Nurs 1995;21(1):34-40.
8. Buchbauer G, Jirovetz L, Jager W, et al. Aromatherapy: Evidence for sedative
effects of the essential oil of lavender after inhalation. Z Naturforsch [C] 1991;
46(11-12):1067-1072.
9. Guillemain J, Rousseau A, Delaveau P. [Neurodepressive effects of the essen-
tial oil of Lavandula angustifolia Mill]. Ann Pharm Fr 1989;47(6):337-343.
10. Wolfe N. Can aromatherapy oils promote sleep in severely demented patients?
International Journal of Geriatric Psychiatry 1996;11:926-927.
11. Ripple GH, Gould MN, Stewart JA, et al. Phase I clinical trial of perillyl alcohol
administered daily. Clin Cancer Res 1998;4(5):1159-1164.
12. Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K et
al. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four
times a day. Clin Cancer Res 2000;6(2):390-396.
13. Dale A, Cornwell S. The role of lavender oil in relieving perineal discomfort
following childbirth: A blind randomized clinical trial. J Adv Nurs 1994;19(1):89-96.
14. Brandao FM. Occupational allergy to lavender oil. Contact Dermatitis 1986;
15(4):249-250.
15. Schaller M, Korting HC. Allergic airborne contact dermatitis from essential oils
used in aromatherapy. Clin Exp Dermatol 1995;20(2):143-145.
16. Coulson IH, Khan AS. Facial ‘pillow’ dermatitis due to lavender oil allergy.
Contact Dermatitis 1999;41(2):111.
17. Saeki Y. The effect of foot-bath with or without the essential oil of lavender on
the autonomic nervous system: A randomized trial. Complement Ther Med 2000;
8(1):2-7.
18. Rademaker M. Allergic contact dermatitis from lavender fragrance in Difflam
gel. Contact Dermatitis 1994;31(1):58-59.
76 JOURNAL OF HERBAL PHARMACOTHERAPY
19. Varma S, Blackford S, Statham BN, et al. Combined contact allergy to tea tree
oil and lavender oil complicating chronic vulvovaginitis. Contact Dermatitis 2000;
42(5):309-310.
20. Atanassova-Shopova S, Roussinov KS. On certain central neurotropic effects of
lavender essential oil. Izv Inst Fiziol (Sofiia) 1970;13:69-77.
21. Ziegler J. Raloxifene, retinoids, and lavender: “Me too” tamoxifen alternatives
under study [news]. J Natl Cancer Inst 1996;88(16):1100-1102.
22. Zweibel J, Ho P, Sepelak SB, et al. Clinical trials referral resource. Clinical tri
-
als with perillyl alcohol. Oncology (Huntingt) 1997;11(12):1817, 1820.
23. Clegg RJ, Middleton B, Bell GD, White DA. The mechanism of cyclic monoterpene
inhibition of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase in vivo in the
rat. J Biol Chem 1982;257(5):2294-2299.
24. Ren Z, Gould MN. Inhibition of ubiquinone and cholesterol synthesis by the
monoterpene perillyl alcohol. Cancer Lett 1994;76(2-3):185-190.
25. Elisabetsky E, Marschner J, Souza DO. Effects of linalool on glutamatergic sys
-
tem in the rat cerebral cortex. Neurochem Res 1995;20(4):461-465.
26. Gamez MJ, Jimenez J, Navarro C, et al. Study of the essential oil of Lavandula
dentata L. Pharmazie 1990;45(1):69-70.
27. Lis-Balchin M, Hart S. Studies on the mode of action of the essential oil of lav-
ender (Lavandula angustifolia P. Miller). Phytother Res 1999;13(6):540-542.
28. Fulton GJ, Barber L, Svendsen E, et al. Oral monoterpene therapy (perillyl alco-
hol) reduces vein graft intimal hyperplasia. J Surg Res 1997;69(1):128-134.
29. Elegbede JA, Elson CE, Qureshi A, Tanner MA, Gould MN. Inhibition of
DMBA-induced mammary cancer by the monoterpene d-limonene. Carcinogenesis
1984;5(5):661-664.
30. Haag JD, Gould MN. Mammary carcinoma regression induced by perillyl alco-
hol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 1994;34(6):
477-483.
31. Mills JJ, Chari RS, Boyer IJ, Gould MN, Jirtle RL. Induction of apoptosis in
liver tumors by the monoterpene perillyl alcohol. Cancer Res 1995;55(5):979-983.
32. Lantry LE, Zhang Z, Gao F, et al. Chemopreventive effect of perillyl alcohol on
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced tumorigenesis in (C3H/HeJ
X A/J)F1 mouse lung. J Cell Biochem Suppl 1997;27:20-25.
33. Hohmann J, Zupko I, Redei D, et al. Protective effects of the aerial parts of Sal
-
via officinalis, Melissa Officinalis and Lavandula angustifolia and their constituents
against enzyme-dependent and enzyme-independent lipid peroxidation. Planta Med
1999;65(6):576-578.
34. Jager W, Buchbauer G, Jirovetz L, et al. Percutaneous absorption of lavender oil
from massage oil. J Soc Cosm Chem 1992;43:49-54.
35. Motomura N, Sakurai A, Yotsuya Y. A psychophysiological study of lavender
odorant. Memoirs of Osaka Kyoiku University, Series III 1999;47(2):281-287.
36. Itai T, Amayasu H, Kuribayashi M, et al. Psychological effects of aromatherapy
on chronic hemodialysis patients. Psychiatry Clin Neurosci 2000;54(4):393-397.
37. Buckle J. Aromatherapy. Nurs Times 1993;89(20):32-35.
38. Diego MA, Jones NA, Field T, et al. Aromatherapy positively affects mood,
EEG patterns of alertness and math computations. Int J Neurosci 1998; 96(3-4):
217-224.
Monograph from Natural Standard 77
39. Ghelardini C, Galeotti N, Salvatore G, et al. Local anaesthetic activity of the es
-
sential oil of Lavandula angustifolia. Planta Med 1999;65(8):700-703.
40. Lis-Balchin M, Hart S. A preliminary study of the effect of essential oils on
skeletal and smooth muscle in vitro. J Ethnopharmacol 1997;58:183-187.
41. Yamada K, Kimaki Y, Ashida Y. Anticonvulsive effects of inhaling lavender oil
vapour. Biol Pharm Bull 1994;17(2):359-360.
42. Burke YD, Stark MJ, Roach SL, et al. Inhibition of pancreatic cancer growth by
the dietary isoprenoids farnesol and geraniol. Lipids 1997;32(2):151-156.
43. Reddy BS, Wang CX, Samaha H, Lubet R, Steele VE, Kelloff GJ, et al.
Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res
1997;57(3):420-425.
78 JOURNAL OF HERBAL PHARMACOTHERAPY
For FACULTY/PROFESSIONALS with journal subscription
recommendation authority for their institutional library . . .
Please send me a complimentary sample of this journal:
(please write complete journal title here–do not leave blank)
If you have read a reprint or photocopy of this article, would you like to
make sure that your library also subscribes to this journal? If you have
the authority to recommend subscriptions to your library, we will send you
a free complete (print edition) sample copy for review with your librarian.
1. Fill out the form below and make sure that you type or write out clearly both the name
of the journal and your own name and address. Or send your request via e-mail to
getinfo@haworthpress.com including in the subject line “Sample Copy Request” and
the title of this journal.
2. Make sure to include your name and complete postal mailing address as well as your
institutional/agency library name in the text of your e-mail.
[Please note: we cannot mail specific journal samples, such as the issue in which a specific article appears.
Sample issues are provided with the hope that you might review a possible subscription/e-subscription with
your institution's librarian. There is no charge for an institution/campus-wide electronic subscription
concurrent with the archival print edition subscription.]
I will show this journal to our institutional or agency library for a possible subscription.
Institution/Agency Library: ______________________________________________
Name: _____________________________________________________________
Institution: __________________________________________________________
Address: ___________________________________________________________
City: ____________________
Return to: Sample Copy Department, The Haworth Press, Inc.,
10 Alice Street, Binghamton, NY 13904-1580
State: __________ Zip: ____________________
